

Anti-CTLA4 & PD-1 Reference Antibody (Vudalimab)

Catalog # APR11618

Product Information


Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P16410 & Q15116
Reactivity	Human
Clonality	Bispecific
Isotype	Half IgG+ScFv

Additional Information


Target/Specificity	CTLA-4 / CD152, PDCD1 / PD-1 / CD279
Expression system	CHO

Protein Information

Images




Anti-CTLA4 & PD-1 Reference Antibody (Vudalimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.





The purity of Anti-CTLA4 & PD-1 Reference Antibody (Vudalimab) is 98.25%, determined by SEC-HPLC.


Vudalimab bound to CTLA4 protein, and then rebounded to secondary antibodies (Anti-human-IgG-Fc-HRP), and read OD450. As shown in fig, Vudalimab bound to hu-CTLA4-His, and the EC50 was 0.480 nM.




Vudalimab bound to PD-1 protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Vudalimab bound to huPD-1-His, and the EC50 was 0.090 nM.




Vudalimab bound to CTLA4-CHO-K cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcy PE) , and test by flow cytometry. As shown in fig, Vudalimab bound to CTLA4-CHO-K cells, and the EC50 was 20.150 nM.



Vudalimab bound to huPD-1-Jurkat cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcy PE) , and test by flow cytometry. As shown in fig, Vudalimab bound to huPD-1-Jurkat cells, and the EC50 was 2.508 nM.



Co-incubation of Vudalimab with PD-1-NF-AT-Jurkat and CD3L-huPD-L1-CHO-K cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Vudalimab was able to block the PD-1/PD-L1 signaling pathway.



The detected molecular weight of Anti-CTLA4 & PD-1 Reference Antibody (Vudalimab) is 125.32 kDa.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.